CD163 and cancer: In addition, the COX-2+ cells in the cancer tissue sections accounted for 3%-13% of all the observed M1 TAMs (i.e., CD68+ HLA-DR+ or CD68+ iNOS+ cells), and accounted for 93%-100% of the M2 TAMs observed (CD68+ CD163+ or CD68+ VEGF+).